Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several claims align with the provided label sections (Description, Indications, Mechanism). However, claims about inactive ingredients (sodium citrate, hydrochloric acid, sodium hydroxide) are only partially supported, and the therapy-related claims for DVT/PE omit required warfarin co-administration and timing conditions specified in the label. The mechanism claim that factor Xa inhibition prevents thrombin formation is supported, and the statement that thrombin is essential for clot formation is not expressly stated in the provided label text.
Category Scores
Accurate Statements
Arixtra is a synthetic, selective factor Xa inhibitor.
11 DESCRIPTION: 'synthetic and specific inhibitor of activated Factor X (Xa)'
Arixtra works by selectively inhibiting activated factor X (factor Xa).
12.1 Mechanism of Action: 'selective inhibition of Factor Xa' and 11 DESCRIPTION
Inhibition of factor Xa prevents the formation of thrombin.
12.1 Mechanism of Action: 'Neutralization of Factor Xa interrupts the blood coagulation cascade and thus inhibits thrombin formation and thrombus development.'
Unsupported Statements
Arixtra (fondaparinux sodium) contains sodium citrate as an inactive ingredient.
11 DESCRIPTION lists sodium chloride/water for injection and may contain sodium hydroxide and/or hydrochloric acid as pH adjusters, but does not mention sodium citrate.
Arixtra (fondaparinux sodium) contains hydrochloric acid as an inactive ingredient.
11 DESCRIPTION states it 'May also contain sodium hydroxide and/or hydrochloric acid as pH adjusters,' which supports presence of hydrochloric acid but not specifically classifying it as an 'inactive ingredient' in the provided text.
Arixtra (fondaparinux sodium) contains sodium hydroxide as an inactive ingredient.
11 DESCRIPTION states it 'May also contain sodium hydroxide and/or hydrochloric acid as pH adjusters,' which supports presence of sodium hydroxide but not specifically classifying it as an 'inactive ingredient' in the provided text.
Arixtra (fondaparinux sodium) contains water for injection as an inactive ingredient.
11 DESCRIPTION states the isotonic solution contains sodium chloride and water for injection, but does not explicitly label it as an 'inactive ingredient.'
Thrombin is essential for clot formation.
12.1 Mechanism of Action states Factor Xa neutralization 'inhibits thrombin formation and thrombus development,' but it does not expressly state 'thrombin is essential for clot formation.'
Contradictions
Low
AI Statement
Arixtra is used to treat deep vein thrombosis (DVT) in adults.
Label Reference
1.2 Treatment of Acute Deep Vein Thrombosis in Adult Patients: 'indicated ... when administered in conjunction with warfarin sodium.'
Low
AI Statement
Arixtra is used to treat pulmonary embolism (PE) in adults.
Label Reference
1.3 Treatment of Acute Pulmonary Embolism in Adult Patients: 'when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital.'
Important Omissions
For DVT treatment: label specifies use 'in conjunction with warfarin sodium.'
Importance:
Moderate
For PE treatment: label specifies 'in conjunction with warfarin sodium' and 'when initial therapy is administered in the hospital.'
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The omission of required warfarin co-administration/timing for labeled DVT and PE treatment could lead to incomplete or incorrect regimen representation relative to the label. Other inaccuracies relate to ingredient categorization and an unlabelled causal assertion about thrombin.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Treatment indications for acute DVT and acute PE are incomplete because the label requires specific warfarin co-administration (and hospital initial therapy for PE).
Suggested Improvement
Rewrite DVT and PE treatment claims to include the label-required conjunction with warfarin sodium and PE hospital initial therapy. For inactive ingredients, rely on the label phrasing ('may also contain ... as pH adjusters') rather than asserting they are 'inactive ingredients' unless explicitly stated.